QUALITY BY DESIGN BASED DISSOLUTION TEST DEVELOPMENT OF OMEPRAZOLE EXTENDED RELEASE FORMULATION
Abstract
Objective: The objective of the current work is to develop dissolution method for the formulation contains mix pellets of omeprazole delayed release
(DR) and extended release.
Methods: The dissolution method design was based on the quality by design principles, the selection of dissolution media, apparatus and drug
release specification was based on scientific understanding of drug release mechanism and stability of omeprazole. Design of experiments (DOE)
employed to assess the huskiness of the dissolution test using pH, volume of media and concentration of surfactant as critical test parameters.
Results: Omeprazole DDR formulation shows more than 85% cumulative drug release at 105 minutes with the % RSD less than 5 among six units.
Based on p values (<0.1) of Shapiro-Wilk test for normality, Response-1 and 2 are statistically analysed with ANOVA statistics. The ANOVA analysis
shows significant effect of ‘volume' and ‘pH' of dissolution media (p<0.05) on Quality Target Test Profile.
Conclusion: The outcome of DOE assessed with 95% confidence interval ANOVA statistics, which reveals that the dissolution test is rugged and can
be used for routine quality control test of omeprazole dual DR formulation.
Keywords: Dissolution, Development, Omeprazole, Quality by design, Design of experiments, ANOVA.
Downloads
References
Prasanthi NL, Rao NR, Manikiran SS. Studies on dissolution enhancement of poorly water soluble drug usig water soluble carriers. Asian J Pharm Clin Res 2010;3(2):95-7.
Van Buskirk GA. Dissolution testing as a quality control tool during scale-up of immediate release oral, solid dosage form. Dissolution Technol 1995;2(3):3-8.
Kramer J, Grady LT, Gajendran J. Historical development of dissolution testing. In: Dressman J, Krämer J, editors. Pharmaceutical Dissolution Testing. Boca Raton, FL: Taylor & Francis Group; 2005. p. 1-37.
Anand O, Yu LX, Conner DP, Davit BM. Dissolution testing for generic drugs: An FDA perspective. AAPS J 2011;13(3):328-35.
USFDA & CDER: Guidance for Industry Dissolution Testing of Immediate Release Solid Oral Dosage Forms. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070237.pdf. [Last seen on 2014 Oct 21; Last cited on 1997 Aug].
Vaghela B, Kayastha R, Bhatt N. Development and validation of dissolution procedures. J Appl Pharm Sci 2011;1(3):50-6.
Kramer J, Steinmetz R, Stippler E. Dissolution method development with a view to quality control. In: Dressman J, Krämer J, editors. Pharmaceutical Dissolution Testing. Boca Raton, FL: Taylor & Francis Group; 2005. p. 315-49.
Dickinson PA, Lee WW, Stott PW, Townsend AI, Smart JP, Ghahramani P, et al. Clinical relevance of dissolution testing in quality by design. AAPS J 2008;10(2):380-90.
Trivedi B. Quality by design (QbD) in pharmaceuticals. Int J Pharm Pharm Sci 2012;4(1):17-29.
Lingam M, Almareddy RS, Vagisha S. Modified Release Benzi Imidazole Formulations. United States Patent WO2012092486 A2. Dr. Reddy’s Laboratories, Inc.; 2012.
Farinha A, Bica A, Martins JM, Pais JP. Dissolution of omeprazole from delayed-release solid oral dosage forms. Drug Dev Ind Pharm 2000;26(7):785-90.
Mathew M, Gupta VD, Rodney EB. Stability of omeprazole solutions at various ph values as determined by high-performance liquid chromatography. Drug Dev Ind Pharm 1995;21(8):965-71.
Klein S, Wunderlich M, Dressman J. Development of dissolution tests on the basis of gastrointestinal physiology. In: Dressman J, Krämer J, editors. Pharmaceutical Dissolution Testing. Boca Raton, FL: Taylor & Francis Group; 2005. p. 193-227.
Stippler E, Kopp S, Dressman J. Comparison of US pharmacopeia simulated intestinal fluid TS (without pancreatin) and phosphate standard buffer pH 6.8, TS of the international pharmacopoeia with respect to their use in in vitro dissolution testing. Dissolution Technol 2004;11(2):6-10.
Manranjan VC, Yadav DS, Jogia HA, Chauhan PL. Design of experiment (DOE) utilization to develop a simple and robust reversed-phase HPLC technique for related substances’ estimation of omeprazole formulations. Sci Pharm 2013;81(4):1043-56.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.